Partnership Brings Innovative Immunotherapy Clinical Trial to Area
Duke University and Providence have teamed together to bring modern immunotherapy clinical trial options to patients at Providence Cancer Center. This innovative study is for those who have resected (or ablated) hepatic metastases from colorectal cancer and have completed chemotherapy.
The “PANVAC Trial” is a multicenter, randomized phase II study of vaccine- induced active immunotherapy with PANVAC (viral vector) or autologous, cultured dendritic cells infected with PANVAC. The primary objective is improved progression-free survival beyond that achieved with surgical resection and chemotherapy alone. This is an opportunity for physicians to select their own plan for resection (or ablation) and systemic chemotherapy, while still offering their patients a clinical trial that includes an immunotherapy component in their treatment plan. The patients will continue to follow up with their surgeon and medical oncologist for long-term surveillance.
For more information and/or to enroll patients, please contact Todd Crocenzi, M.D., at 503-215-5696 or Katie Strauss, R.N., at 503-215-2619.
See other clinical trial information
Providence Gastroenterology Oncology Program Contacts
- Todd Crocenzi, MD, director
503-215-5696 - Katie Strauss, RN
503-215-2619